HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials

Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer

(2015) Michael Kloth et al.   GUT

Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

(2015) Emanuele Valtorta et al.   MODERN PATHOLOGY

The genomic landscape of response to EGFR blockade in colorectal cancer

(2015) Andrea Bertotti et al.   NATURE

HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment

(2015) S. M. Kavuri et al.   Cancer Discovery

HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics

(2014) Peter A. Fasching et al.   BREAST CANCER RESEARCH AND TREATMENT

Comparison of HER2 expression between primary colorectal cancer and their corresponding metastases

(2014) Won-Suk Lee et al.   Cancer Medicine

HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab

(2013) F. Sclafani et al.   ANNALS OF ONCOLOGY

Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials

(2013) George Fountzilas et al.   BMC CANCER

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients

(2013) V Martin et al.   BRITISH JOURNAL OF CANCER

A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: Results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO)

(2013) Gary Middleton et al.   EUROPEAN JOURNAL OF CANCER

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial

(2013) Matthew T Seymour et al.   LANCET ONCOLOGY

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

(2013) Jean-Yves Douillard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab

(2012) George Fountzilas et al.   Journal of Translational Medicine

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer

(2011) A. Bertotti et al.   Cancer Discovery

Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers

(2010) Andreas H. Marx et al.   HUMAN PATHOLOGY

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?

(2009) Dara O Kavanagh et al.   BMC CANCER

KRASandBRAFMutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial

(2009) Susan D. Richman et al.   JOURNAL OF CLINICAL ONCOLOGY

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

(2008) C. Gravalos et al.   ANNALS OF ONCOLOGY

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

(2008) M Hofmann et al.   HISTOPATHOLOGY